February 13, 2018 / 9:11 PM / 8 months ago

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

Feb 13 (Reuters) - Neurocrine Biosciences Inc:

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

* Q4 REVENUE $94.5 MILLION

* NEUROCRINE BIOSCIENCES- REVENUE MILESTONES UNDER ABBVIE AGREEMENT FOR 2018 EXPECTED TO BE $40 MILLION CONTINGENT ON FDA APPROVAL OF ELAGOLIX FOR ENDOMETRIOSIS

* ‍ONGOING OPERATING EXPENSES FOR 2018 SHOULD APPROXIMATE $365 MILLION TO $395 MILLION​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below